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Abstract
Glucocorticoids (GC), produced and released by the adrenal glands, regulate numerous 
physiological processes in a wide range of tissues. Because of their profound immunosuppressive 
and anti-inflammatory actions, GC are extensively used for the treatment of immune and 
inflammatory conditions, the management of organ transplantation, and as a component of 
chemotherapy regimens for cancers. However, both pathologic endogenous elevation and long-
term use of exogenous GC are associated with severe adverse effects. In particular, excess GC has 
devastating effects on the musculoskeletal system. GC increase bone resorption and decrease 
formation leading to bone loss, microarchitectural deterioration and fracture. GC also induce loss 
of muscle mass and strength leading to an increased incidence of falls. The combined effects on 
bone and muscle account for the increased fracture risk with GC. This review summarizes the 
advance in knowledge in the last two decades about the mechanisms of action of GC in bone and 
muscle and the attempts to interfere with the damaging actions of GC in these tissues with the goal 
of developing more effective therapeutic strategies.
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1. CLINICAL EFFECTS OF GLUCOCORTICOIDS ON THE 
MUSCULOSKELETAL SYSTEM
Excess of glucocorticoids (GC) in humans produces detrimental effects in a wide range of 
tissues. Fat tissue increases and redistributes to abdomen, shoulders, and face, a diabetic 
metabolic syndrome evolves, blood pressure increases causing hypertensive disease, skin 
thins and ecchymosis and pink striae appear, acne and hirsutism and irregular menstruation 
develop, kidney stones form, and there is a failure of growth in children [1–3]. However, 
among the most common and serious effects occur in the musculoskeletal system [1–3]. In 
bone, excess GC causes osteoporosis and osteonecrosis, whereas in skeletal muscle, GC 
causes proximal myopathy and muscle atrophy [3,4] (Figure 1A). The combined detrimental 
effects of GC on bone mass and muscle strength causes falls and results in increased bone 
fracture risk, which is a major clinical feature of GC excess. In children GC also markedly 
retard skeletal growth and maturation [5]. Both endogenous elevation of GC, caused by 
cortisol over-secretion from the adrenal cortex due to adrenal disease or to ACTH 
stimulation by pituitary disease or by ectopic tissue, or exogenous GC administered for the 
treatment of a serious disorder, lead to the same phenotype, commonly known as Cushing 
syndrome. Exogenous GC produce similar adverse effects on bone and muscle to those in 
endogenous GC excess, regardless of the underlying chronic disease being treated with 
exogenous GC. The majority of patients with endogenous GC elevations exhibit 
osteoporosis (64%) and myopathy (65%) and approximately half of these individuals 
experience fractures (Figure 1A [3,6–10]). The fractures can occur at any skeletal site but 
commonly affect vertebrae and ribs (Figure 1B) One study reported that 26% of patients 
receiving chronic oral corticosteroid developed osteoporosis as defined by bone mineral 
density ( BMD) t-scores equal to or lower than −2.5 [11]. However, some studies indicate 
that BMD alone underestimates the fracture risk for patients on GC treatment [11,12]. The 
myopathy induced by GC increases the incidence of falls and leads to a further increase in 
fracture risk.
The biological effect of GC and the pathophysiology of excess GC result from activation of 
the nuclear GC receptor (GR) (Figure 1C), which regulates a large number and wide 
spectrum of genes controlling cell metabolism [13]. Mutations in the GR gene, prevent the 
Cushingoid phenotype from developing [14]. Absence of the phenotype also occurs if the 
11β-hydroxysteroid dehydrogenase type1 (11β-HSD1), which converts inactive to active GC 
metabolites, is defective [13,15,16], or if there is a defect in a coenzyme, H6PDH [17,18]. 
11β-HSD1 regulates the level of cortisol and its inactive precursor, cortisone, in target 
tissues (Figure 1C) [19]. Hydroxylation of the 11-carbon position in GC is essential for 
activity, and 11β-HSD1 regulates the conversion of inactive cortisol analogues such as 
prednisone to prednisolone, the active form. The clinical features of GC on bone and muscle 
varies in severity depending on the endogenous activity of 11β-HSD1.
In most patients with disease caused by endogenous hormonal activity, the high secretion 
rate of GC relates to the severity of the complications, whereas the side effects in disease 
caused by exogenous GC excess relate to the dose of hormonal analogue, its potency, and 
the length of treatment. A number of analogues are currently in clinical use in doses 
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equivalent to the anti-inflammatory activity of cortisol (Figure 1D). However, largely 
because of higher affinities for GR, their pharmacokinetics differ and biological half-lives 
are longer than cortisol, thus increasing their potency [20]. All GC are strong anti-
inflammatory drugs, and patients chronically treated for over one month with high dose of 
GC of over 5mg prednisone or its equivalent often have severe musculoskeletal side effects. 
However, even relatively small doses of GC in the order of 1.5mg/day, such as those used for 
treatment of asthma, cause adrenal suppression and may lead to adverse effects on the 
skeletal system [21]. GC cause adverse effects on bone and muscle mainly by direct action 
on the GR expressed in bone and muscle cells. However, GC also indirectly affect bone and 
muscle adversely by suppressing sex steroid secretion [22,23], lowering serum 1,25 
dihydroxy-Vitamin D levels and calcium absorption [24], decreasing collagen synthesis [25], 
and inducing diabetes mellitus [26].
Whether GC in the normal range affect the musculoskeletal system is an unsettled, but 
central question [27]. There is some evidence in children that cortisol in the normal range 
negatively effects bone geometry and density [28]. In bone, 11β-HSD1 increases with age 
and increased cortisol production locally may account in part for age-related bone loss [29]. 
The report of a negative relationship between circulating cortisone and bone formation 
markers and BMD supports such a finding [30]. Further, cortisol is higher in women with 
lower BMD at the hip, which in turn appears to relate to GC receptor polymorphisms [31]. A 
better understanding of the role of normal GC levels in determining bone mass and muscle 
function awaits much more extensive studies. However, there is little disagreement that 
states of increased cortisol secretion due to chronic stress such as burns [32–34] and 
alcoholism [35] increase the incidence of osteoporosis and muscle atrophy. The clinical 
effects of GC excess are dose and time dependent and many of the features are reversible 
with removal of the excess. Both BMD and myopathy improve by discontinuing the 
treatment. On the other hand, fracture and osteonecrosis are adverse events that require 
prevention. Thus, a comprehensive understanding of the mechanism of action of GC on bone 
and muscle cells is essential both for understanding the pathophysiology of the clinical 
presentation of disease and for the development of drug treatments. Currently, replacement 
of GC with drugs that do not have serious effects on the musculoskeletal system is not 
always possible.
1. Bone: Osteoporosis and Osteonecrosis
Skeletal fractures are a common and well-recognized clinical manifestation of both 
endogenous and exogenous chronic GC. Fractures of the ribs and vertebrae occur frequently 
(Figure 1B). Surprisingly, femoral fracture is not a feature documented in published cases of 
endogenous Cushing syndrome [1–3], whereas it is a prominent feature of exogenous GC 
use [36–41]. This difference is probably because exogenous GC increase hip fracture risk by 
exacerbating a reduction in age-related bone mass and an increase in frequency of age-
related falls.
Studies suggest that fracture occurs with GC excess at a higher BMD than in age-related 
osteoporosis indicating that decrease in bone quality with chronic GC play an important role 
in fracture risk [11,42]. However, not all studies agree [43]. What is a consistent finding is 
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that the low BMD occurs in the presence of obesity induced by GC, whereas simple obesity 
is associated with normal to high BMD [44,45]. Acute GC administration decreases bone 
formation and increases bone resorption [46,47]. However, the increased bone resorption 
phase does not persist and the osteoporosis of chronic GC use has low to normal bone 
turnover. Histologically, there is a decrease in bone volume, trabecular width, osteoid 
surface, and mineralization rate [48]. In GC induced osteoporosis, both bisphosphonates, 
perhaps paradoxically in view of the low bone turnover, and intermittent PTH increase BMD 
and reduce fracture [49].
Osteonecrosis (also called avascular necrosis or aseptic necrosis) is a rare disease [50,51], 
but it occurs commonly with chronic GC use [4,52]. Pathogenesis, although not proven, may 
to be due to interruption of the blood supply to bone with death of osteocytes and 
destruction of normal bone structure [53,54]. Multiple etiologies are involved [55]. In 
osteonecrosis induced by GC, the precise pathogenesis is unclear but may relate to GC 
effects on fat in the bone marrow. In general, its occurrence relates to the length of exposure 
and dose of GC although even relatively small doses of GC given over short time periods 
may precipitate the disease. In patients with inflammatory disease prescribed 4mg 
methylprednisone 21 tablet taper-pack over 6 days, the relative risk of osteonecrosis 
increases with one pack and rises further with multiple packs [56]. Common skeletal sites 
are in bones contiguous with large joints, including head of the femur and humerus, femur 
and tibia at the knee joint, and bones of the wrist and foot [55]. Radiological imaging 
establishes the diagnosis, with magnetic resonance imaging being most sensitive and 
standard radiography most commonly used. In the vertebrae, it may be difficult to 
distinguish a crush fracture due to osteonecrosis from that due to osteoporosis. Treatment is 
unsatisfactory particularly in end-stage disease, and bisphosphonates, although often 
advocated, showed no benefit in clinical trial [57].
2. Muscle: Myopathy and Muscle Atrophy
Proximal myopathy can be a striking clinical feature of Cushing syndrome [10,58,59]. The 
pathogenesis is obscure. It is similar clinically to the proximal myopathy of vitamin D 
deficiency and other endocrine myopathies and may have a common mechanism. It is most 
noticeable at the hip girdle muscles and rising from a sitting position and climbing stairs are 
difficult. It regresses with the removal of the GC excess. In asthmatics, the myopathy may 
affect the diaphragm and worsen respiratory distress [60]. The terms myopathy and muscle 
atrophy are not interchangeable. The former indicates the muscle fibers are normal in size 
and number but are dysfunctional, whereas the latter indicates the muscle fibers are smaller, 
fewer, and wasted. Muscle atrophy with GC excess is associated with abnormalities in 
transcription factors, nuclear cofactors, hyperacetylation, cell-calcium metabolism and 
insulin signaling [61,62]. GC excess also has major effects on muscle protein synthesis and 
degradation, and myoblast proliferation [63]. Atrophy affects all voluntary muscles and may 
be difficult to recognize because of the concomitant increase in fat. Clinically it manifests as 
both generalized peripheral and central weakness.
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2. GLUCOCORTICOID EFFECTS ON BONE CELLS
1. Effects of GC excess on the bone remodeling rate and osteonecrosis
GC induce osteoporosis by increasing bone resorption, decreasing bone formation, and 
increasing apoptosis of osteocytes and osteoblasts, resulting in decreased bone strength 
causing elevated fracture risk in humans and animal models of GC excess [12,41,64–71] 
(Figure 2). The initial phase of GC-induced bone loss occurs rapidly with reports of BMD 
loss as early as 3–5 months after initiation of immunosuppressant therapy in patients [72–
74] and with losses of 6–12% after the first year of GC treatment [75]. This early bone-loss 
phase is characterized by robust resorption activity; however, inhibition of osteoid 
production and osteoblast and osteocyte apoptosis also contribute to the rapid bone loss 
exhibited in this phase. The increased resorption is attributed to GC effects on both 
prolonging the lifespan of pre-existing osteoclasts as well as a transient, initial increase of 
osteoclastogenesis [64,76,77]. Bone formation is also readily suppressed by GC in short-
term intervention models [78,79], which is attributed to the downregulation of osteocalcin 
(OCN) [80,81] and collagen 1 (Col1A1) [82,83] resulting in decreased production of 
osteoid. GC also increase the prevalence of apoptotic osteoblasts and osteocytes, which 
occurs as early as 10 days after GC initiation in mouse models and accumulates with 
continued administration [65,70,78,84].
Long-term treatment of GC induces bones losses after the first year of up to 3–5% per 
continued year of GC therapy [75]. However, it should be noted that the bone changes in 
humans is confounded by the activity and etiology of the underlying disease for which 
exogenous GC are being used to treat. In contrast to the initial phase of GC-induced bone 
loss, the chronic phase is characterized by reductions in resorption activity and osteoclast 
number, which is attributed to the loss of receptor activator of NFKB ligand (RANKL)- 
expressing osteoblastic cells required for osteoclast development [70]. The reduced bone 
formation and apoptosis of osteoblasts and osteocytes exhibited in the early phase continues 
throughout long-term GC exposure, corresponding to the strong correlations between the 
cumulative GC dose and the percentage of BMD loss exhibited in patients [72]. Thus, 
imbalance between formation and resorption causing negative bone balance might be 
responsible for the continuous bone loss in chronic GC excess states.
A recent study in a murine model of GC excess examined the temporal sequence of 
pathogenic events leading to GC-induced osteonecrosis and provided evidence that the 
femoral head is more sensitive to the adverse effects of GC excess compared to other 
anatomic bone sites [85]. The femoral head of mice given GC exhibited decreased 
expression of the hypoxia-inducible factor (Hif-1α) and vascular endothelial growth factor 
(VEGF), a reduction in the number of osteoblasts, bone formation rate, and strength and an 
increase in number of osteoclasts, before changes were detected in either the femoral 
midshaft cortex or the cancellous bone of the distal femur. These molecular and cellular 
effects in the femoral head were accompanied by conversion of the normal vasculature to 
areas of edema as assessed by magnetic resonance imaging providing diagnostic evidence of 
osteonecrosis. These effects of GC preceded any detectable changes in bone density, cortical 
or cancellous bone architecture, bone volume in the cortical midshaft or distal cancellous 
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bone, or accumulation of empty osteocyte lacunae (a late sign of osteocyte apoptosis). These 
findings strongly suggest that alterations in bone vascularity leading to osteonecrosis 
precede bone loss and deterioration of bone microarchitecture, and explain the vulnerability 
of the femoral head to collapse in GC excess.
A separate study showed that GC-induced osteonecrosis in a murine model as well as in 
human bone is associated with decreased remodeling of the osteocyte lacunar space and with 
decreased expression of metalloproteinase 13 (MMP13) by these cells [86]. Suppression of 
MMP13 expression occurs in parallel, but independently of GC-induced osteocyte apoptosis; 
and the changes in matrix hypermineralization characteristic of osteonecrosis occur before 
any detectable reduction in bone mass induced by GC. These findings suggest that 
suppression of osteocytic perilacunar remodeling is an early event associated with 
osteonecrosis induced by GC [86].
2. Direct effects of GC on cells of the osteoblastic lineage
Endogenous GC activity is regulated by two enzymes: 11β-HSD type 1 and type 2 (Figure 
1C). 11β-HSD1 is a nicotinamide adenine dinucleotide phosphate (NADPH)-dependent 
reductase that converts inert 11-ketometabolites into biologically active GC; whereas 11β-
HSD2 is a nicotinamide adenine dinucleotide (NAD+)-dependent dehydrogenase that 
converts active GC into inactive metabolites. Several transgenic overexpression mouse 
models have taken advantage of this enzymatic system to investigate the direct effects of GC 
on osteoblastic cells. By overexpressing 11β-HSD2 under the control of promoters active at 
different stages of differentiation of the lineage, GC action can be blocked in a cell specific 
manner. Blocking GC action by overexpressing 11β-HSD2 in osteoblast precursors, 
immature as well as mature osteoblasts, using the 3.6-kb or 2.3-kb fragments of the rat 
Col1a1 promoter, decreases bone mass accrual in growing mice, highlighting the importance 
of GC signaling for physiological bone development and growth [87–89]. Similarly, mice 
lacking the GR in cells expressing the osteoblast specific transcription factor Runt Related 
Transcription Factor 2 (Runx2) also exhibit reductions in cancellous bone accompanied by 
reduced expression of osteoblast-related genes (Runx2, Col1a1, and Bglap2) [83]. The 
impact of endogenous GC signaling on early osteoblastic linage cells decreases with age, as 
no differences in bone volume or cancellous bone parameters were found in skeletally 
mature 24-week old Col1a1-2.3kb-11β-HSD2 compared to control mice [90]. In addition, 
transgenic expression of 11β-HSD2 in mature osteoblasts and osteocytes under the control 
of the osteocalcin promoter does not negatively affect skeletal development or peak bone 
mass accrual [66]. Overall, the evidence indicates that GC signaling in early osteoblastic 
differentiation stages, but not in late osteoblastic or osteocytic stages, is required for optimal 
bone mass acquisition during bone growth.
In contrast, mice overexpressing 11β-HSD2 under the control of the murine osteocalcin 
gene 2 (OG2) promoter, which is active only in mature osteoblasts and osteocytes [91,92] 
were protected from GC-induced apoptosis of these cells [66]. Prevention of osteoblast/
osteocyte apoptosis preserved cancellous osteoblast function and osteoid production, thus 
preventing the decrease in bone formation. Importantly, bone strength was preserved in the 
transgenic mice despite loss of bone mass, suggesting a potential effect of osteocyte viability 
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in preserving bone strength. In addition, the initial rapid bone loss induced by GC was not 
prevented by blocking GC action in osteoblasts and osteocytes, strongly suggesting that the 
early phase of bone loss is due to GC action on osteoclasts [64] (see below Effects of GC 
excess on osteoclasts).
A major effect of GC on cells of the osteoblastic lineage is the inhibition of osteoblast 
differentiation and reduction of the synthetic activity of osteoblasts. This action is dependent 
upon the duration of the exposure and the dose of GC, and the stage of differentiation of the 
osteoblasts. Low GC doses or short durations of in vitro administration of embryonic or 
adult mesenchymal stem cells (MSC), as well as immature osteoblast progenitor cells, 
promote early osteoblastic differentiation with increases in the mRNA expression of 
osteoblastic genes [1,93]. In contrast, higher GC doses and longer exposure of cells 
committed to the osteoblastic lineage suppress differentiation and inhibit the expression of 
osteoblast markers [94,95]. At least part of the inhibitory effect of high dose GC on 
osteoblast maturation and matrix production is due to direct downregulation of osteoblastic 
genes, including collagen 1 and osteocalcin [80–83].
3. GC and osteoblast and osteocyte apoptosis: inside-out kinase signaling, reactive 
oxygen species (ROS), and endoplasmic reticulum (ER) stress
A hallmark of GC excess on cells of the osteoblastic lineage is the promotion of apoptosis 
[12,70] (Figure 2). The increase in the prevalence of osteoblast apoptosis partially explains 
the reduced osteoblast number and decreased bone formation induced by GC. Further, 
accumulation of apoptotic osteocytes contributes to osteoporosis of GC excess. As discussed 
earlier, GC induce apoptosis by direct actions on osteoblasts and osteocytes as in vivo 
blockade of GC signaling in these cells preserved viability [66]. Accordingly, the apoptotic 
effect of GC observed in vivo are readily reproduced in vitro in cultured osteoblasts and 
osteocytes and depend on the expression of the glucocorticoid receptor (GR) [96,97].
Binding of GC to the GR is followed by cis- or trans-interactions between the ligand-bound 
receptor with DNA and induction or repression of gene transcription [98,99]. However, GC 
also exert actions mediated by the GR independently of direct changes in gene transcription, 
including modulation of the activity of intracellular kinases such as the extracellular signal-
regulated kinases (ERKs), the c-Jun N-terminal kinase (JNK) and the proline-rich tyrosine 
kinase 2 (Pyk2) [100–105]. Pyk2 also known as related adhesion focal tyrosine kinase 
(RAFTK), cellular adhesion kinase β (CAKβ), and calcium-dependent tyrosine kinase 
(CADTK) [106,107] is a member of the focal adhesion kinase (FAK) family of non-receptor 
tyrosine kinases. Although Pyk2 and FAK are highly homologous, they exhibit opposite 
effects on cell fate. Whereas FAK activation leads to cell spreading and survival, Pyk2 
induces cell detachment and apoptosis [106,108]. In particular, the survival of osteoblasts 
and osteocytes and their interaction with the extracellular matrix are controlled by focal 
adhesions, sites at the plasma membrane in which integrins connect extracellular matrix 
proteins with intracellular structural and catalytic molecules [109–111]. Signaling mediated 
by integrins is bidirectional. Extracellular matrix proteins induce integrin engagement and 
activate intracellular signaling (referred to as outside-in signaling). Conversely, activation of 
intracellular signaling or changes in the composition of the focal adhesions regulate the 
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interaction of integrins with extracellular matrix proteins (referred to as inside-out signaling) 
[112,113]. Whereas association of integrins with the extracellular matrix leads to survival, 
loss of this interaction causes detachment-induced apoptosis or anoikis [111]. For 
osteocytes, integrin engagement mediated by FAK, and potentiated by mechanical signals, 
maintains osteocyte survival [114]. Conversely, the pro-apoptotic effect of GC in osteocytes 
is preceded by cell detachment due to interference with FAK-mediated survival signaling 
generated by integrins [97]. GC oppose this integrin/FAK-dependent anti-apoptotic signaling 
by activating Pyk2, which in turn activates pro-apoptotic JNK signaling. This rapid kinase 
activation is followed by inside-out signaling that causes osteocyte detachment and leads to 
anoikis. Remarkably, although this action of GC is exerted via a receptor-mediated 
mechanism, it is independent of new gene transcription [97]. This evidence highlights the 
importance of alterations in rapid kinase signaling independent of nuclear actions of the GR 
and open new avenues for the design of GC analogs with the ability to activate transcription-
mediated versus kinase-mediated actions of the GR.
Changes in FAK and Pyk2 kinase signaling induced by GC, combined with down-regulation 
of genes that prolong survival, such as interleukin-6, insulin growth factors, transforming 
growth factor β, collagenase type I, and integrin β1 [98,115–118], could result in the 
increase in osteocyte and osteoblast apoptosis observed in vivo.
GC also increase reactive oxygen species (ROS) production in bone in vivo and in 
osteoblasts in vitro [119], which could contribute to their in vivo effects. Endoplasmic 
reticulum (ER) stress is associated with increased ROS, resulting from accumulation of 
misfolded/unfolded proteins, and can trigger apoptosis. ER stress is alleviated by 
phosphorylation of eukaryotic translation initiation factor 2α (eIF2α), which slows the 
global rate of protein translation to provide time for the ER to recover from the excessive 
protein load, thus allowing the cell to escape from apoptosis [120,121]. Consistent with a 
role for ROS/ER stress, GC effects are prevented by the compounds, salubrinal and 
guanabenz [122], eIF2α dephosphorylation inhibitors that block ROS-induced ER stress 
[123,124]. Salubrinal and guanabenz prevented the pro-apoptotic effect of GC on osteoblasts 
and osteocytes in vitro as well as the decrease in differentiation induced by GC in 
osteoblastic cell cultures. Further, salubrinal prevented apoptosis of osteoblasts and 
osteocytes in vivo and blunted the decrease in bone mass and bone formation induced by 
GC. Salubrinal increased the number of alkaline phosphatase positive colonies in bone 
marrow cell cultures [125] and osteocalcin expression in osteoblastic MC3T3-E1 cells [126]. 
Conversely in vitro exposure to thapsigargin or tunicamycin induces elevated ER stress and 
increased apoptosis of osteoblasts and changes in osteoblast differentiation [127,128]. 
Increased ER stress appears to have a time-dependent biphasic effect inducing rapid increase 
in osteoblast markers Runx2 and osterix, followed by a reduction in the expression of these 
transcription factors as well as osteocalcin [127].
4. Effects of GC excess on osteoclasts
One of the features of GC-induced bone loss is a rapid, early increase in bone resorption, 
which is associated with increased osteoclasts on bone surfaces (Figure 2). The effect of GC 
on osteoclasts results from two different mechanisms: GC stimulate osteoclast generation 
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and also prolong the life span of preexisting osteoclasts. GC increase the RANKL/
osteoprotegerin (OPG) ratio in bone, mainly by downregulating the expression of OPG, a 
Wnt/β catenin target gene, resulting in increased osteoclast generation [129,130]. Consistent 
with this notion, activation of Wnt/β catenin signaling prevents osteoclast increase and halts 
bone resorption induced by GC [129]. In addition, GC promote survival of osteoclasts [76], 
and oppose the pro-apoptotic effects of bisphosphonates [64]. The effect of GC delaying 
osteoclast apoptosis explains why mice receiving GC exhibit increased number of 
osteoclasts on bone surfaces even when osteoclast progenitors in the bone marrow are 
reduced. GC exert an anti-apoptotic effect on osteoclasts by direct actions on osteoclasts 
demonstrated by the evidence that GC do not increase osteoclasts in mice expressing 11β-
HSD2 specifically in these cells [76]. Consistent with a causative role of delayed osteoclast 
apoptosis in the early bone loss induced by GC, the loss of bone observed in WT mice was 
prevented in transgenic mice expressing 11β-HSD2 specifically in osteoclasts. Remarkably, 
these mice exhibit the expected decrease in osteoblast number and bone formation rate and 
increased osteoblast apoptosis [76]. Thus, GC act on cells of the osteoclastic and 
osteoblastic lineage independently and by different mechanisms.
In contrast to the early, acute increased osteoclast and decreased osteoblast activity, late 
effects of GC decrease both osteoclasts and osteoblasts [131]. Whereas osteoblast number is 
reduced and osteoblast and osteocyte apoptosis is increased at all stages of GC-induced bone 
disease, at the late stage inhibition of osteoclastogenesis prevails over delayed osteoclast 
apoptosis. The latter effect is attributed to a reduction in osteoblastic lineage cells that 
support osteoclastogenesis and leads to the low bone remodeling rate that characterizes 
chronic GC-induced bone disease.
5. GC and Wnt/β-catenin signaling
Wnt/β-catenin signaling and GC action lead to opposing effects on bone. The Wnt/β-catenin 
pathway has a critical role in the control of bone acquisition and maintenance. This pathway 
is activated by ligands of the Wnt family that bind to frizzled receptors and co-receptors, and 
also by downregulation of antagonists, including Dkk1 and Sost/sclerostin [132]. Human 
mutations responsible for high bone mass diseases, including gain-of-function of the LRP5 
Wnt co-receptor, loss of expression of the Sost/sclerostin inhibitor in Van Buchem disease 
and sclerosteosis type 1, and loss-of-function of the sclerostin chaperone LRP4 in 
sclerosteosis type 2, demonstrate that activation of the Wnt/β-catenin pathway is linked to 
increased bone formation and bone gain [133–135]. In addition however, genetic 
manipulation of β-catenin, the mediator of the canonical Wnt pathway, affects bone 
resorption. This is due to up-regulation of OPG, the decoy receptor for RANKL [136,137]. 
Therefore, the Wnt/β-catenin signaling cascade regulates bone mass by both bone anabolic 
and anti-catabolic mechanisms. Further, activation of Wnt/β-catenin signaling promotes 
osteoblast and osteocyte survival [138]. This collective evidence demonstrates that activation 
of the Wnt/β-catenin signaling pathway and GC action lead to opposing cellular and tissue 
level effects on bone. Based on this findings, we recently investigated the effects of GC 
excess in mice exhibiting activated Wnt/β-catenin signaling by virtue of genetic deletion of 
the Wnt antagonist Sost/sclerostin (Sost−/− mice) [129]. Sost−/− mice were protected from 
the decrease in bone mass, deterioration in microarchitecture, and reduced structural and 
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material strength induced by GC. Although the high bone mass exhibited by Sost−/− mice is 
due to increased bone formation with unchanged resorption, protection from bone loss in 
Sost−/− mice was due to prevention of GC-induced bone resorption and not to restoration of 
bone formation. In WT mice, GC increased the expression of Sost and the number of 
sclerostin positive osteocytes. GC also altered the molecular signature of the Wnt/β-catenin 
pathway by decreasing expression of genes associated with both anti-catabolism, including 
OPG, as well as anabolism/survival. In contrast, GC did not decrease OPG or other anti-
catabolic markers in Sost−/− mice, but did reduce genes associated with anabolism and 
survival. Thus, in the context of GC excess, activation of Wnt/β-catenin signaling induced 
by Sost/sclerostin deficiency sustained bone integrity by opposing bone catabolism despite 
markedly reduced bone formation and increased apoptosis. These results indicate that the 
Wnt/β-catenin pathway, which is predominantly anabolic for bone, is switched to anti-
catabolic in the frame of GC excess.
These findings suggest that therapeutic interventions activating Wnt/β-catenin signaling 
could halt the high bone resorption responsible for the early rapid bone loss induced by GC, 
which in humans ranges 6–12% during the first year of treatment [12]. Consistent with this 
notion, inhibition of sclerostin with a neutralizing antibody in growing mice opposed the 
lack of bone gain and the loss of strength induced by GC [139,140]. It was proposed that 
these effects were due to preservation of osteoblast activity [140]. However, compared to 
control mice treated with GC alone, mice treated with GC and the anti-sclerostin antibody 
exhibited lower circulating tartrate-resistant acid phosphatase (TRAP5b), a marker of 
osteoclast number, [139] and CTX-1 [140], but still markedly reduced bone formation 
markers osteocalcin and amino-terminal propeptide (PINP) [139]. Similarly, GC are unable 
to decrease OPG and increase the RANKL/OPG ratio ex vivo in bones from Sost−/− mice or 
from WT mice treated with an anti-sclerostin antibody [129]. These findings demonstrate 
that Sost/sclerostin deficiency, either genetically or pharmacologically achieved, maintains 
bone mass and strength in conditions of GC excess by inhibiting bone resorption through 
sustained anti-catabolic signaling driven by OPG.
This crosstalk between GC and Wnt/β-catenin signaling could be exploited therapeutically 
not only to halt bone resorption and bone loss induced by GC, but also to inhibit the 
exaggerated bone formation and bone mass in diseases due to hyperactivation of Wnt/β-
catenin signaling. Indeed, it has been shown that GC stopped the bone gain and reduced high 
P1NP in a patient with Van Buchem disease, a genetic disease that results from lack of 
sclerostin expression and in which continuous bone anabolism causes life-threatening 
increased intracranial pressure [141]. Prior to GC intervention, the patient exhibited annual 
BMD gains of 4 to 9% in the lumbar spine and of 4 to 24% in the hip. Treatment with 
prednisone blunted the anabolic effect of Sost deficiency as evidenced by no gain in BMD 
over two years (−0.7% in lumbar spine and 0.4% in the hip). The demonstration that bone 
formation and Wnt/β-catenin anabolic signaling is decreased in Sost/sclerostin deficient 
mice treated with GC [129] provides a mechanistic explanation for these clinical findings. 
Thus, GC oppose the effects of Sost/sclerostin deficiency on bone formation in both humans 
and mice [129,141].
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Inhibition of resorption with bisphosphonates is current standard of care for GC-induced 
osteoporosis [12,142], as these drugs protect from the loss of bone mass in animal models 
and patients. However, bone formation is decreased even further by bisphosphonates 
compared to GC alone [49,78,122,143]. In patients receiving GC, treatment with anti-
RANKL antibody induced more pronounced reductions in bone formation compared to 
bisphosphonate [144]. Profound reduction in bone turnover is undesirable since it increases 
the potential for developing osteonecrosis of the jaw and atypical femoral fracture [145–
148]. In contrast to bisphosphonates, Sost deficiency confers high bone formation, and Sost 
deficient mice treated with GC exhibit bone formation levels comparable to WT mice treated 
with placebo [129]. Even when the reduction in P1NP induced by GC in Sost−/− mice is 
more severe than in WT mice, the reduced P1NP is similar to that of placebo-treated WT 
mice. Similarly, the reduced bone formation exhibited by Sost−/− mice treated with GC is 
equivalent to bone formation in placebo-treated WT mice. Therefore, Sost/sclerostin 
deficiency maintains tissue-level toughness by preserving modest amounts of bone 
formation while preventing GC-induced increases in resorption. This finding points to a 
potential benefit of neutralizing sclerostin strategies compared to the current therapeutic 
approach to treat GC-induced bone fragility.
In summary, the deleterious effects of GC on the skeleton are linked to increased expression 
of the osteocyte-derived Wnt/β-catenin antagonist Sost/sclerostin and to downregulation of 
Wnt/β-catenin target genes; and Sost/sclerostin deficiency prevents GC-induced 
osteoporosis by anti-catabolic, not anabolic, actions.
3. GLUCOCORTICOID EXCESS IN MUSCLE AND ATROPHY-RELATED 
GENES IN BONE AND MUSCLE
1. Effects of GC excess in muscle
GC induce loss of skeletal muscle mass and strength particularly at the hip and shoulder 
girdle, which in turn increase the risk of falls. These effects on muscle are of rapid onset and 
detected as early as 7 days after initiation of GC administration in humans [149,150]. GC 
reduce sarcolemma excitability, decrease serum levels of creatine kinase and myoglobin, 
decrease cross sectional area of type 1, 2A and 2B myofibers, and reduce the specific force 
(strength) of muscle fibers. Muscle atrophy induced by GC is accompanied by suppression 
of protein synthesis with simultaneous increase in protein catabolism, leading to reduced 
myotube diameter [61,151]. The formation of new myotubes is also impaired, as GC inhibit 
myogenesis by down-regulating myogenin gene expression. GC-induced protein catabolism 
in skeletal muscle is associated with enhanced Forkhead Box O (FoxO)-dependent 
transcription of members of the protein degradation machinery, including the ubiquitin-
proteasome system of E3 ubiquitin ligases, the lysosomal system of cathepsins, and the 
calcium-dependent system of calpains [61,152]. E3 ubiquitin ligases muscle atrophy F-box 
(MAFbx, also known as atrogin1) and muscle RING finger 1 (MuRF1, also known as 
TRIM63) are known regulators of GC-induced muscle atrophy both in vivo and in vitro, as 
well as a number of other sarcopenia-inducing conditions including denervation, 
immobilization, disuse, diabetes, and renal failure [153–155]. Mice lacking MuRF1 are 
partially protected from muscle loss induced by GC, and muscle-specific deletion of the GR 
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prevents the increased atrophy gene expression and muscle loss induced by GC [156–158]. 
The ubiquitin ligase MUSA1 (muscle ubiquitin ligase of the SCF complex in atrophy-1, also 
known as Fbxo30) has also been associated with increased protein catabolism and reductions 
in total protein content in muscle models of denervation injury/disuse [159].
2. Regulation of atrophy related genes in muscle and bone
A recent study in a mouse model of GC excess provided information about the mechanisms 
by which GC upregulate the expression of atrophy-related genes in muscle and demonstrated 
that GC also increase atrophy-related genes in bone [79]. GC increase the expression in bone 
in vivo and in osteoblasts and osteocytes in vitro of the traditionally considered muscle-
specific E3 ligases atrogin1, MuRF1, and MUSA1 (Figure 3). GC also increase the 
expression of Notch ligands, receptors, and target genes in muscle, but not in bone. GC-
induced expression of atrophy-related genes and muscle cell atrophy were prevented by 
pharmacologic inhibition of the Notch pathway. These findings demonstrate that GC-
induced loss of bone and muscle mass are accompanied by increased expression of atrophy-
related genes, although the upstream mechanisms are tissue-specific. Further, they identify 
the Notch signaling pathway as a potential therapeutic intervention to prevent skeletal 
muscle atrophy and weakness induced by GC, and provide the mechanistic basis for 
combining therapies that target each tissue to treat GC-induced osteopenia and sarcopenia.
This evidence notwithstanding, the relevance of atrophy gene expression for the action of 
GC in bone remains unclear. Earlier studies have shown that genetic global deletion in mice 
of MuRF1 protects from the loss of bone induced by hind limb unloading [160]. MuRF1 KO 
mice were also protected from the decrease in bone formation and the increase in osteoclasts 
[160]. This evidence, together with the findings in our study [79], raises the possibility that 
upregulation of MuRF1, and possibly other atrophy-related genes, contributes to the reduced 
bone formation and increased bone resorption induced by GC, and suggests that targeting 
the atrophy pathway may block GC action in bone.
The decrease in muscle mass, quantified by lean body mass, mass of individual muscles rich 
in fast-twitch fibers like the extensor digitorium longus (EDL) induced by GC in our murine 
model, is detected as early as after 14 days of GC administration [79]. Importantly, muscles 
from GC-treated mice exhibited decreased strength (force), quantified ex vivo by 
contractility tests of individual muscles, and in vivo, by measuring isometric plantarflexion 
torque generated by muscles of the posterior compartment of the leg. Remarkably, we 
detected decreased strength (specific force) in the slow-twitch soleus muscle in the absence 
of reduction of soleus mass, suggesting that GC might alter muscle function in the absence 
of detectable tissue loss, at least in muscles traditionally considered resistant to GC 
[161,162]. In contrast, the reduction in strength in the EDL muscle can be explained by loss 
of muscle mass, because it is corrected by normalizing for tissue mass. The lower rate of 
fatigue detected in the fast-twitch EDL muscles treated with GC compared to placebo-
treated muscles may be explained by the fact that EDL muscles are mainly composed of the 
highly fatigable myosin-rich type 2 fibers, which are preferential targets of GC-induced 
muscle atrophy [163,164]. Thus, GC might induce loss of highly fatigable fibers and the 
remaining fibers fatigue more slowly in EDL muscles. In contrast, slow-twitch soleus 
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muscles fatigue at the same rate in GC- and placebo-treated mice despite reductions in 
overall strength. This effect may in part explain the proximal myopathy seen in patients with 
Cushing syndrome. The current findings with the C57BL/6 mouse model of GC excess are 
consistent with the previously reported reduction in muscle fiber specific force in humans 
treated with GC [150]. Importantly, the reduction in muscle mass correlated with increased 
expression of the atrophy genes. Future studies are warranted to establish the role of E3 
ubiquitin ligases in muscle weakness induced by GC.
GC decrease C2C12 myotube diameter by 20%, comparable with earlier in vitro and in vivo 
studies [150,157,158,162,165], as well as studies with starvation [162,166] and denervation 
[158,166]. Decreases of 10–17% myotube diameter translates into reductions of 25–35% in 
strength (specific force) with GC administration in humans, suggesting that modest 
reductions in myotube diameter result in a notable impairment of muscle function [150].
Activation of the Notch signaling pathway is required for expansion of a satellite cell 
population, a known critical event for skeletal muscle repair [167,168]. Notch signaling also 
inhibits myogenic differentiation of progenitor cells by decreasing myoblast determination 
protein 1 (MyoD) and myogenin expression and by reducing MyoD activity [167,169,170]. 
These findings support the notion that Notch signaling is crucial for maintaining the self-
renewal capacity of muscle satellite cells. The recent findings showing that the expression of 
components of the Notch pathway was upregulated by GC in skeletal muscle reveal a novel 
role of this pathway. [79]. Moreover, the fact that inhibition of Notch signaling with the 
gamma secretase inhibitor, GSI XX, blocked the upregulation of atrophy-related genes and 
prevented the reduction in C2C12 myotube diameter induced by GC, suggest a potential 
therapeutic benefit of blocking Notch signaling to maintain muscle strength.
In contrast to the effects on muscle, GC did not increase the expression of components of the 
Notch pathway in vivo, ex vivo, or in vitro models of bone and osteoblastic/osteocytic cells 
[79]. This finding is consistent with previous studies demonstrating that the expression Dll1 
and Jag1 Notch ligands was not altered by GC administered to osteoblastic cells [171]. 
Thus, GC activate Notch signaling in muscle, but not in bone, to induce atrophy. Although 
the mechanism underlying the upregulation of atrophy genes by GC in bone remains 
unknown, it is possible that Forkhead box O (FoxO) transcription factors are involved. In 
muscle, FoxO family members (FoxO1, 3, and 4) regulate atrogen-related gene expression 
and are required for the full atrophic response by several inducers of skeletal muscle 
wasting, including starvation, denervation, and chronic kidney disease [165,166,172]. In 
bone, FoxOs are activated by and are critical for the defense against ROS [173]. In addition, 
at least part of the effects of GC in bone are due to accumulation of ROS as well as to ER 
stress, and are abolished by ROS or ER stress inhibitors [122]. Activation of FoxO in 
osteoblasts by GC is blocked by ROS inhibition [119]. FoxO-mediated transcription is 
favored over Wnt/β-catenin transcription [119], and activation of Wnt/β-catenin signaling 
protects from GC-induced osteoporosis [129]. Future studies will be required to reveal the 
role of FoxOs in the upregulation of atrophy-related genes by GC in bone.
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4. CONCLUSIONS AND FUTURE STUDIES
Research in the last two decades have enormously increased our understanding of the 
mechanisms of action of GC excess in the musculoskeletal system. It is now clear that GC 
act directly on individual bone cell types (osteoclasts, osteoblasts and osteocytes) (Figure 2), 
and that they also affect muscle cells. GC stimulate the production of osteoclasts and delay 
apoptosis, thus increasing number and resorption activity, primarily in the early phase of GC 
bone disease. GC induce the premature death of osteoblasts and markedly decrease their 
matrix synthesizing activity, resulting in marked decreased bone formation rate throughout 
GC treatment. GC increase apoptosis of osteocytes, contributing to deterioration of the 
osteocytic canalicular network, which is crucial for the regulation of bone metabolism and 
function. GC increase the expression of the osteocyte-derived bone formation antagonist 
Sost/sclerostin, which in turn decreases Wnt/β-catenin signaling and reduces OPG 
expression contributing to the increase in bone resorption. GC induce in both muscle and 
bone the expression of atrophy-related genes (Figure 3), which are involved in muscle and 
bone atrophy. GC are important therapeutic agents for many chronic diseases, but they 
produce serious adverse effects on the musculoskeletal system. Future research is urgently 
required to develop therapeutic interventions that simultaneously prevent the loss of bone 
and muscle mass and preserve the functionality of musculoskeletal tissues. In addition, 
clinical studies on early osteonecrosis and cell biology studies to clarify the mechanisms that 
lead to osteonecrosis are needed to develop preventative and curative treatment. Further, 
studies to clarify differences between myopathy and muscle atrophy and the development of 
therapeutic interventions for prevention and treating myopathy induced by GC are 
warranted.
Acknowledgments
Funding: This research was supported by the National Institutes of Health (grants AR059357, AT008754, 
AT008754-O2S1, and CA209882 to TB) and the United States Department of Veterans Affairs (I01BX002104-01 
to TB). AYS was partially supported by T32-AR065971.
References
1. Plotz CM, Knowlton AI, Ragan C. The natural history of Cushing’s syndrome. Am J Med. 1952; 
13:597–614. [PubMed: 12996538] 
2. Soffer LJ, Iannacconone A, Gabrilove JL. Cushing’s syndrome. American Journal of Medicine. 
1961; 30:129–146.
3. Ross EJ, Linch DC. Cushing’s syndrome--killing disease: discriminatory value of signs and 
symptoms aiding early diagnosis. Lancet. 1982; 2:646–649. [PubMed: 6125785] 
4. Littooij AS, Kwee TC, Enriquez G, et al. Whole-body MRI reveals high incidence of osteonecrosis 
in children treated for Hodgkin lymphoma. Br J Haematol. 2017; 176:637–642. [PubMed: 
27891588] 
5. Aljebab F, Choonara I, Conroy S. Systematic Review of the Toxicity of Long-Course Oral 
Corticosteroids in Children. PLoS ONE. 2017; 12:e0170259. [PubMed: 28125632] 
6. Gudbjornsson B, Juliusson UI, Gudjonsson FV. Prevalence of long term steroid treatment and the 
frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice. Ann 
Rheum Dis. 2002; 61:32–36. [PubMed: 11779755] 
7. Overman RA, Gourlay ML, Deal CL, et al. Fracture rate associated with quality metric-based anti-
osteoporosis treatment in glucocorticoid-induced osteoporosis. Osteoporos Int. 2015; 26:1515–
1524. [PubMed: 25600474] 
Sato et al. Page 14
Clin Rev Bone Miner Metab. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
8. Canalis E, Mazziotti G, Giustina A, et al. Glucocorticoid-induced osteoporosis: pathophysiology 
and therapy. Osteoporos Int. 2007; 18:1319–1328. [PubMed: 17566815] 
9. Batchelor TT, Taylor LP, Thaler HT, et al. Steroid myopathy in cancer patients. Neurology. 1997; 
48:1234–1238. [PubMed: 9153449] 
10. Bowyer SL, LaMothe MP, Hollister JR. Steroid myopathy: incidence and detection in a population 
with asthma. J Allergy Clin Immunol. 1985; 76:234–242. [PubMed: 4019954] 
11. Van Staa TP, Laan RF, Barton IP, et al. Bone density threshold and other predictors of vertebral 
fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003; 48:3224–3229. 
[PubMed: 14613287] 
12. Weinstein RS. Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med. 2011; 
365:62–70. [PubMed: 21732837] 
13. Chapman K, Holmes M, Seckl J. 11beta-hydroxysteroid dehydrogenases: intracellular gate-keepers 
of tissue glucocorticoid action. Physiol Rev. 2013; 93:1139–1206. [PubMed: 23899562] 
14. Charmandari E, Kino T, Chrousos GP. Primary generalized familial and sporadic glucocorticoid 
resistance (Chrousos syndrome) and hypersensitivity. Endocr Dev. 2013; 24:67–85. [PubMed: 
23392096] 
15. Tomlinson JW, Draper N, Mackie J, et al. Absence of Cushingoid phenotype in a patient with 
Cushing’s disease due to defective cortisone to cortisol conversion. J Clin Endocrinol Metab. 
2002; 87:57–62. [PubMed: 11788623] 
16. Arai H, Kobayashi N, Nakatsuru Y, et al. A case of cortisol producing adrenal adenoma without 
phenotype of Cushing’s syndrome due to impaired 11beta-hydroxysteroid dehydrogenase 1 
activity. Endocr J. 2008; 55:709–715. [PubMed: 18493111] 
17. Draper N, Walker EA, Bujalska IJ, et al. Mutations in the genes encoding 11beta-hydroxysteroid 
dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase 
deficiency. Nat Genet. 2003; 34:434–439. [PubMed: 12858176] 
18. Lavery GG, Idkowiak J, Sherlock M, et al. Novel H6PDH mutations in two girls with premature 
adrenarche: ‘apparent’ and ‘true’ CRD can be differentiated by urinary steroid profiling. Eur J 
Endocrinol. 2013; 168:K19–K26. [PubMed: 23132696] 
19. Morgan SA, Hassan-Smith ZK, Lavery GG. Mechanisms in endocrinology: Tissue-specific 
activation of cortisol in Cushing’s syndrome. Eur J Endocrinol. 2016; 175:R83–R89. [PubMed: 
26957494] 
20. Swartz SL, Dluhy RG. Corticosteroids: clinical pharmacology and therapeutic use. Drugs. 1978; 
16:238–255. [PubMed: 209958] 
21. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and 
meta-analysis. Arch Intern Med. 1999; 159:941–955. [PubMed: 10326936] 
22. Crilly RG, Marshall DH, Nordin BE. Metabolic effects of corticosteroid therapy in post-
menopausal women. J Steroid Biochem. 1979; 11:429–433. [PubMed: 158677] 
23. Lukert BP, Johnson BE, Robinson RG. Estrogen and progesterone replacement therapy reduces 
glucocorticoid-induced bone loss. J Bone Min Res. 1992; 7:1063–1069.
24. Crilly, RG., Marshall, DH., Horsman, A., Nordin, BEC., Peacock, M. Corticosteroid Osteoporosis. 
In: Dixon, ASJ.Russell, RGG., Stamp, TCB., editors. Osteoporosis, A Multi-Disciplinary Problem. 
Academic Press Inc and Royal Society of Medicine; London: 1983. p. 153-159.
25. Oikarinen A, Haapasaari KM, Sutinen M, et al. The molecular basis of glucocorticoid-induced skin 
atrophy: topical glucocorticoid apparently decreases both collagen synthesis and the corresponding 
collagen mRNA level in human skin in vivo. Br J Dermatol. 1998; 139:1106–1110. [PubMed: 
9990383] 
26. Schwartz AV. Diabetes Mellitus: Does it Affect Bone? Calcif. Tissue Int. 2003; 73:515–519.
27. Cooper MS. Glucocorticoids in bone and joint disease: the good, the bad and the uncertain. Clin 
Med (Lond). 2012; 12:261–265. [PubMed: 22783780] 
28. Shi L, Sanchez-Guijo A, Hartmann MF, et al. Higher glucocorticoid secretion in the physiological 
range is associated with lower bone strength at the proximal radius in healthy children: importance 
of protein intake adjustment. J Bone Miner Res. 2015; 30:240–248. [PubMed: 25196629] 
Sato et al. Page 15
Clin Rev Bone Miner Metab. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
29. Cooper MS, Rabbitt EH, Goddard PE, et al. Osteoblastic 11beta-hydroxysteroid dehydrogenase 
type 1 activity increases with age and glucocorticoid exposure. J Bone Miner Res. 2002; 17:979–
986. [PubMed: 12054173] 
30. Cooper MS, Syddall HE, Fall CH, et al. Circulating cortisone levels are associated with 
biochemical markers of bone formation and lumbar spine BMD: the Hertfordshire Cohort Study. 
Clin Endocrinol (Oxf). 2005; 62:692–697. [PubMed: 15943831] 
31. van Schoor NM, Dennison E, Lips P, et al. Serum fasting cortisol in relation to bone, and the role 
of genetic variations in the glucocorticoid receptor. Clin Endocrinol (Oxf). 2007; 67:871–878. 
[PubMed: 17681029] 
32. Suman OE, Spies RJ, Celis MM, et al. Effects of a 12-wk resistance exercise program on skeletal 
muscle strength in children with burn injuries. J Appl Physiol (1985 ). 2001; 91:1168–1175. 
[PubMed: 11509512] 
33. Przkora R, Herndon DN, Sherrard DJ, et al. Pamidronate preserves bone mass for at least 2 years 
following acute administration for pediatric burn injury. Bone. 2007; 41:297–302. [PubMed: 
17561466] 
34. Norbury WB, Herndon DN, Branski LK, et al. Urinary cortisol and catecholamine excretion after 
burn injury in children. J Clin Endocrinol Metab. 2008; 93:1270–1275. [PubMed: 18211976] 
35. Besemer F, Pereira AM, Smit JW. Alcohol-induced Cushing syndrome. Hypercortisolism caused 
by alcohol abuse. Neth J Med. 2011; 69:318–323. [PubMed: 21934176] 
36. Van Staa TP, Leufkens HG, Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone 
Miner Res. 2001; 16:581–588. [PubMed: 11277277] 
37. Van Staa TP, Abenhaim L, Cooper C, et al. Public health impact of adverse bone effects of oral 
corticosteroids. Br J Clin Pharmacol. 2001; 51:601–607. [PubMed: 11422020] 
38. Van Staa TP, Leufkens HGM, Abenhaim L, et al. Use of oral corticoisteroids and risk of fractures. 
J Bone Min Res. 2000; 15:993–1000.
39. Walsh LJ, Wong CA, Oborne J, et al. Adverse effects of oral corticosteroids in relation to dose in 
patients with lung disease. Thorax. 2001; 56:279–284. [PubMed: 11254818] 
40. Hubbard RB, Smith CJ, Smeeth L, et al. Inhaled corticosteroids and hip fracture: a population-
based case-control study. Am J Respir Crit Care Med. 2002; 166:1563–1566. [PubMed: 
12406825] 
41. Van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced 
osteoporosis. Calcif Tissue Int. 2006; 79:129–137. [PubMed: 16969593] 
42. Luengo M, Picado C, Del Rio L, et al. Vertebral fractures in steroid dependent asthma and 
involutional osteoporosis: a comparative study. Thorax. 1991; 46:803–806. [PubMed: 1771602] 
43. Selby PL, Halsey JP, Adams KR, et al. Corticosteroids do not alter the threshold for vertebral 
fracture. J Bone Min Res. 2000; 15:952–956.
44. Yang S, Shen X. Association and relative importance of multiple obesity measures with bone 
mineral density: the National Health and Nutrition Examination Survey 2005–2006. Arch 
Osteoporos. 2015; 10:14. [PubMed: 25957066] 
45. Zhu K, Hunter M, James A, et al. Associations between body mass index, lean and fat body mass 
and bone mineral density in middle-aged Australians: The Busselton Healthy Ageing Study. Bone. 
2015; 74:146–152. [PubMed: 25652209] 
46. Cosman F, Nieves J, Herbert J, et al. High-dose glucocorticoids in multiple sclerosis patients exert 
direct effects on the kidney and skeleton. J Bone Miner Res. 1994; 9:1097–1105. [PubMed: 
7942157] 
47. Dovio A, Perazzolo L, Osella G, et al. Immediate fall of bone formation and transient increase of 
bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients 
with multiple sclerosis. J Clin Endocrinol Metab. 2004; 89:4923–4928. [PubMed: 15472186] 
48. Aaron JE, Francis RM, Peacock M, et al. Contrasting microanatomy of idiopathic and 
corticosteroid-induced osteoporosis. Clin Orthop Relat Res. 1989:294–305.
49. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced 
osteoporosis. N Engl J Med. 2007; 357:2028–2039. [PubMed: 18003959] 
50. Cooper C, Steinbuch M, Stevenson R, et al. The epidemiology of osteonecrosis: findings from the 
GPRD and THIN databases in the UK. Osteoporos Int. 2010; 21:569–577. [PubMed: 19547906] 
Sato et al. Page 16
Clin Rev Bone Miner Metab. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
51. Ikeuchi K, Hasegawa Y, Seki T, et al. Epidemiology of nontraumatic osteonecrosis of the femoral 
head in Japan. Mod Rheumatol. 2015; 25:278–281. [PubMed: 25036228] 
52. Kubo T, Ueshima K, Saito M, et al. Clinical and basic research on steroid-induced osteonecrosis of 
the femoral head in Japan. J Orthop Sci. 2016; 21:407–413. [PubMed: 27062553] 
53. Assouline-Dayan Y, Chang C, Greenspan A, et al. Pathogenesis and natural history of 
osteonecrosis. Semin Arthritis Rheum. 2002; 32:94–124. [PubMed: 12430099] 
54. Weinstein RS. Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin 
North Am. 2012; 41:595–611. [PubMed: 22877431] 
55. Murphey MD, Foreman KL, Klassen-Fischer MK, et al. From the radiologic pathology archives 
imaging of osteonecrosis: radiologic-pathologic correlation. Radiographics. 2014; 34:1003–1028. 
[PubMed: 25019438] 
56. Dilisio MF. Osteonecrosis following short-term, low-dose oral corticosteroids: a population-based 
study of 24 million patients. Orthopedics. 2014; 37:e631–e636. [PubMed: 24992058] 
57. Chen CH, Chang JK, Lai KA, et al. Alendronate in the prevention of collapse of the femoral head 
in nontraumatic osteonecrosis: a two-year multicenter, prospective, randomized, double-blind, 
placebo-controlled study. Arthritis Rheum. 2012; 64:1572–1578. [PubMed: 22127729] 
58. Khaleeli AA, Edwards RH, Gohil K, et al. Corticosteroid myopathy: a clinical and pathological 
study. Clin Endocrinol (Oxf). 1983; 18:155–166. [PubMed: 6851197] 
59. Gupta A, Gupta Y. Glucocorticoid-induced myopathy: Pathophysiology, diagnosis, and treatment. 
Indian J Endocrinol Metab. 2013; 17:913–916. [PubMed: 24083177] 
60. Janssens S, Decramer M. Corticosteroid-induced myopathy and the respiratory muscles. Report of 
two cases. Chest. 1989; 95:1160–1162. [PubMed: 2707077] 
61. Schakman O, Gilson H, Thissen JP. Mechanisms of glucocorticoid-induced myopathy. J 
Endocrinol. 2008; 197:1–10. [PubMed: 18372227] 
62. Hasselgren PO, Alamdari N, Aversa Z, et al. Corticosteroids and muscle wasting: role of 
transcription factors, nuclear cofactors, and hyperacetylation. Curr Opin Clin Nutr Metab Care. 
2010; 13:423–428. [PubMed: 20473154] 
63. Morgan SA, Hassan-Smith ZK, Doig CL, et al. Glucocorticoids and 11beta-HSD1 are major 
regulators of intramyocellular protein metabolism. J Endocrinol. 2016; 229:277–286. [PubMed: 
27048233] 
64. Weinstein RS, Chen JR, Powers CC, et al. Promotion of osteoclast survival and antagonism of 
bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest. 2002; 109:1041–
1048. [PubMed: 11956241] 
65. Weinstein RS, Nicholas RW, Manolagas SC. Apoptosis of osteocytes in glucocorticoid-induced 
osteonecrosis of the hip. J Clin Endocrinol Metab. 2000; 85:2907–2912. [PubMed: 10946902] 
66. O’Brien CA, Jia D, Plotkin LI, et al. Glucocorticoids act directly on osteoblasts and osteocytes to 
induce their apoptosis and reduce bone formation and strength. Endocrinology. 2004; 145:1835–
1841. [PubMed: 14691012] 
67. Reid IR. Glucocorticoid osteoporosis--mechanisms and management. Eur J Endocrinol. 1997; 
137:209–217. [PubMed: 9330580] 
68. Plotkin LI, Weinstein RS, Parfitt AM, et al. Prevention of osteocyte and osteoblast apoptosis by 
bisphosphonates and calcitonin. J Clin Invest. 1999; 104:1363–1374. [PubMed: 10562298] 
69. Newell-Price J, Bertagna X, Grossman AB, et al. Cushing’s syndrome. Lancet. 2006; 367:1605–
1617. [PubMed: 16698415] 
70. Weinstein RS. Glucocorticoid-induced osteoporosis. Rev Endocr Metab Disord. 2001; 2:65–73. 
[PubMed: 11708295] 
71. Mazziotti G, Angeli A, Bilezikian JP, et al. Glucocorticoid-induced osteoporosis: an update. Trends 
Endocrinol Metab. 2006; 17:144–149. [PubMed: 16678739] 
72. Van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a 
meta-analysis. Osteoporos Int. 2002; 13:777–787. [PubMed: 12378366] 
73. Laan RFJM, Van Riel PLCM, Van de Putte LBA, et al. Low-dose prednisone induces rapid 
reversible axial bone loss in patients with rheumatoid arthritis: A randomized, controlled study. 
Ann Intern Med. 1993; 119:963–968. [PubMed: 8105737] 
Sato et al. Page 17
Clin Rev Bone Miner Metab. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
74. Devogelaer JP, Adler RA, Recknor C, et al. Baseline glucocorticoid dose and bone mineral density 
response with teriparatide or alendronate therapy in patients with glucocorticoid-induced 
osteoporosis. J Rheumatol. 2010; 37:141–148. [PubMed: 19918047] 
75. LoCascio V, Bonucci E, Imbimbo B, et al. Bone loss in response to long-term glucocorticoid 
therapy. Bone Miner. 1990; 8:39–51. [PubMed: 2306553] 
76. Jia D, O’Brien CA, Stewart SA, et al. Glucocorticoids act directly on osteoclasts to increase their 
lifespan and reduce bone density. Endocrinology. 2006; 147:5592–5599. [PubMed: 16935844] 
77. Hofbauer LC, Zeitz U, Schoppet M, et al. Prevention of glucocorticoid-induced bone loss in mice 
by inhibition of RANKL. Arthritis Rheum. 2009; 60:1427–1437. [PubMed: 19404943] 
78. Plotkin LI, Bivi N, Bellido T. A bisphosphonate that does not affect osteoclasts prevents osteoblast 
and osteocyte apoptosis and the loss of bone strength induced by glucocorticoids in mice. Bone. 
2011; 49:122–127. [PubMed: 20736091] 
79. Sato AY, Richardson D, Cregor M, et al. Glucocorticoids induce bone and muscle atrophy by 
tissue-specific mechanisms upstream of E3 ubiquitin ligases. Endocrinology. 2017; 158:664–677. 
[PubMed: 28359087] 
80. Leclerc N, Noh T, Cogan J, et al. Opposing effects of glucocorticoids and Wnt signaling on 
Krox20 and mineral deposition in osteoblast cultures. J Cell Biochem. 2008; 103:1938–1951. 
[PubMed: 17973254] 
81. Mortensen RF, Shapiro J, Lin BF, et al. Interaction of recombinant IL-1 and recombinant tumor 
necrosis factor in the induction of mouse acute phase proteins. J Immunol. 1988; 140:2260–2266. 
[PubMed: 2450915] 
82. Advani S, LaFrancis D, Bogdanovic E, et al. Dexamethasone suppresses in vivo levels of bone 
collagen synthesis in neonatal mice. Bone. 1997; 20:41–46. [PubMed: 8988346] 
83. Rauch A, Seitz S, Baschant U, et al. Glucocorticoids Suppress Bone Formation by Attenuating 
Osteoblast Differentiation via the Monomeric Glucocorticoid Receptor. Cell Metab. 2010; 11:517–
531. [PubMed: 20519123] 
84. Weinstein RS, Jilka RL, Parfitt AM, et al. Inhibition of osteoblastogenesis and promotion of 
apoptosis of osteoblasts and osteocytes by glucocorticoids: potential mechanisms of their 
deleterious effects on bone. J Clin Invest. 1998; 102:274–282. [PubMed: 9664068] 
85. Weinstein RS, Hogan EA, Borrelli MJ, et al. The Pathophysiological Sequence of Glucocorticoid-
induced Osteonecrosis of the Femoral Head in Male Mice. Endocrinology. 2017
86. Fowler TW, Acevedo C, Mazur CM, et al. Glucocorticoid suppression of osteocyte perilacunar 
remodeling is associated with subchondral bone degeneration in osteonecrosis. Sci Rep. 2017; 
7:44618. [PubMed: 28327602] 
87. Yang M, Trettel LB, Adams DJ, et al. Col3.6-HSD2 transgenic mice: A glucocorticoid loss-of-
function model Spanning early and late osteoblast differentiation. Bone. 2010; 47:573–582. 
[PubMed: 20541046] 
88. Sher LB, Harrison JR, Adams DJ, et al. Impaired cortical bone acquisition and osteoblast 
differentiation in mice with osteoblast-targeted disruption of glucocorticoid signaling. Calcif 
Tissue Int. 2006; 79:118–125. [PubMed: 16927049] 
89. Kalak R, Zhou H, Street J, et al. Endogenous glucocorticoid signalling in osteoblasts is necessary 
to maintain normal bone structure in mice. Bone. 2009; 45:61–67. [PubMed: 19358901] 
90. Sher LB, Woitge HW, Adams DJ, et al. Transgenic expression of 11beta-hydroxysteroid 
dehydrogenase type 2 in osteoblasts reveals an anabolic role for endogenous glucocorticoids in 
bone. Endocrinology. 2004; 145:922–929. [PubMed: 14617568] 
91. Aarden EM, Wassenaar AM, Alblas MJ, et al. Immunocytochemical demonstration of extracellular 
matrix proteins in isolated osteocytes. Histochem Cell Biol. 1996; 106:495–501. [PubMed: 
8950608] 
92. Frendo JL, Xiao G, Fuchs S, et al. Functional hierarchy between two OSE2 elements in the control 
of osteocalcin gene expression in vivo. J Biol Chem. 1998; 273:30509–30516. [PubMed: 9804819] 
93. Cheng SL, Yang JW, Rifas L, et al. Differentiation of human bone marrow osteogenic stromal cells 
in vitro: induction of the osteoblast phenotype by dexamethasone. Endocrinology. 1994; 134:277–
286. [PubMed: 8275945] 
Sato et al. Page 18
Clin Rev Bone Miner Metab. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
94. Ishida Y, Heersche JN. Glucocorticoid-induced osteoporosis: both in vivo and in vitro 
concentrations of glucocorticoids higher than physiological levels attenuate osteoblast 
differentiation. J Bone Miner Res. 1998; 13:1822–1826. [PubMed: 9844099] 
95. Ito S, Suzuki N, Kato S, et al. Glucocorticoids induce the differentiation of a mesenchymal 
progenitor cell line, ROB-C26 into adipocytes and osteoblasts, but fail to induce terminal 
osteoblast differentiation. Bone. 2007; 40:84–92. [PubMed: 16949358] 
96. Gohel A, McCarthy MB, Gronowicz G. Estrogen prevents glucocorticoid-induced apoptosis in 
osteoblasts in vivo and in vitro. Endocrinology. 1999; 140:5339–5347. [PubMed: 10537165] 
97. Plotkin LI, Manolagas SC, Bellido T. Glucocorticoids induce osteocyte apoptosis by blocking focal 
adhesion kinase-mediated survival: evidence for inside-out signaling leading to anoikis. J Biol 
Chem. 2007; 282:24120–24130. [PubMed: 17581824] 
98. Necela BM, Cidlowski JA. Mechanisms of glucocorticoid receptor action in noninflammatory and 
inflammatory cells. Proc Am Thorac Soc. 2004; 1:239–246. [PubMed: 16113441] 
99. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids--new mechanisms for old 
drugs. N Engl J Med. 2005; 353:1711–1723. [PubMed: 16236742] 
100. Druilhe A, Letuve S, Pretolani M. Glucocorticoid-induced apoptosis in human eosinophils: 
mechanisms of action. Apoptosis. 2003; 8:481–495. [PubMed: 12975579] 
101. Limbourg FP, Liao JK. Nontranscriptional actions of the glucocorticoid receptor. J Mol Med. 
2003; 81:168–174. [PubMed: 12682725] 
102. Chauhan D, Pandey P, Ogata A, et al. Dexamethasone induces apoptosis of multiple myeloma 
cells in a JNK/SAP kinase independent mechanism. Oncogene. 1997; 15:837–843. [PubMed: 
9266970] 
103. Blaukat A, Ivankovic-Dikic I, Gronroos E, et al. Adaptor proteins Grb2 and Crk couple Pyk2 with 
activation of specific mitogen-activated protein kinase cascades. J Biol Chem. 1999; 274:14893–
14901. [PubMed: 10329689] 
104. Tokiwa G, Dikic I, Lev S, et al. Activation of Pyk2 by stress signals and coupling with JNK 
signaling pathway. Science. 1996; 273:792–794. [PubMed: 8670418] 
105. Chauhan D, Hideshima T, Pandey P, et al. RAFTK/PYK2-dependent and -independent apoptosis 
in multiple myeloma cells. Oncogene. 1999; 18:6733–6740. [PubMed: 10597281] 
106. Xiong W, Parsons JT. Induction of apoptosis after expression of PYK2, a tyrosine kinase 
structurally related to focal adhesion kinase. J Cell Biol. 1997; 139:529–539. [PubMed: 9334354] 
107. Sasaki H, Nagura K, Ishino M, et al. Cloning and characterization of cell adhesion kinase beta, a 
novel protein-tyrosine kinase of the focal adhesion kinase subfamily. J Biol Chem. 1995; 
270:21206–21219. [PubMed: 7673154] 
108. Avraham H, Park S, Schinkmann K, et al. RAFTK/Pyk2-mediated cellular signalling. Cell Signal. 
2000; 12:123–133. [PubMed: 10704819] 
109. Giancotti FG, Ruoslahti E. Integrin signaling. Science. 1999; 285:1028–1032. [PubMed: 
10446041] 
110. Clark EA, Brugge JS. Integrins and signal transduction pathways: the road taken. Science. 1995; 
268:233–239. [PubMed: 7716514] 
111. Frisch SM, Ruoslahti E. Integrins and anoikis. Curr Opin Cell Biol. 1997; 9:701–706. [PubMed: 
9330874] 
112. Ginsberg MH, Partridge A, Shattil SJ. Integrin regulation. Curr Opin Cell Biol. 2005; 17:509–
516. [PubMed: 16099636] 
113. Hynes R. Integrins: bidirectional, allosteric signaling machines. Cell. 2002; 110:673–687. 
[PubMed: 12297042] 
114. Plotkin LI, Mathov I, Aguirre JI, et al. Mechanical stimulation prevents osteocyte apoptosis: 
requirement of integrins, Src kinases and ERKs. Am J Physiol Cell Physiol. 2005; 289:C633–
C643. [PubMed: 15872009] 
115. Vanden Berghe W, Francesconi E, De Bosscher K, et al. Dissociated glucocorticoids with anti-
inflammatory potential repress interleukin-6 gene expression by a nuclear factor-kappaB-
dependent mechanism. Mol Pharmacol. 1999; 56:797–806. [PubMed: 10496964] 
Sato et al. Page 19
Clin Rev Bone Miner Metab. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
116. Cheng SL, Zhang SF, Mohan S, et al. Regulation of insulin-like growth factors I and II and their 
binding proteins in human bone marrow stromal cells by dexamethasone. J Cell Biochem. 1998; 
71:449–458. [PubMed: 9831081] 
117. Chang DJ, Ji C, Kim KK, et al. Reduction in transforming growth factor beta receptor I 
expression and transcription factor CBFa1 on bone cells by glucocorticoid. J Biol Chem. 1998; 
273:4892–4896. [PubMed: 9478931] 
118. Doherty WJ, Derome ME, McCarthy MB, et al. The effect of glucocorticoids on osteoblast 
function. The effect of corticosterone on osteoblast expression of beta 1 integrins. J Bone Joint 
Surg Am. 1995; 77:396–404. [PubMed: 7890788] 
119. Almeida M, Han L, Ambrogini E, et al. Glucocorticoids and tumor necrosis factor (TNF) alpha 
increase oxidative stress and suppress WNT signaling in osteoblasts. J Biol Chem. 2011; 
286:44326–44335. [PubMed: 22030390] 
120. Harding HP, Zhang Y, Zeng H, et al. An integrated stress response regulates amino acid 
metabolism and resistance to oxidative stress. Mol Cell. 2003; 11:619–633. [PubMed: 12667446] 
121. Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. 
Science. 2011; 334:1081–1086. [PubMed: 22116877] 
122. Sato AY, Tu X, McAndrews KA, et al. Prevention of glucocorticoid induced-apoptosis of 
osteoblasts and osteocytes by protecting against endoplasmic reticulum (ER) stress in vitro and in 
vivo in female mice. Bone. 2015; 73:60–68. [PubMed: 25532480] 
123. Boyce M, Bryant KF, Jousse C, et al. A selective inhibitor of eIF2alpha dephosphorylation 
protects cells from ER stress. Science. 2005; 307:935–939. [PubMed: 15705855] 
124. Tsaytler P, Harding HP, Ron D, et al. Selective inhibition of a regulatory subunit of protein 
phosphatase 1 restores proteostasis. Science. 2011; 332:91–94. [PubMed: 21385720] 
125. Yokota H, Hamamura K, Chen A, et al. Effects of salubrinal on development of osteoclasts and 
osteoblasts from bone marrow-derived cells. BMC Musculoskelet Disord. 2013; 14:197. 
[PubMed: 23816340] 
126. Hamamura K, Tanjung N, Yokota H. Suppression of osteoclastogenesis through phosphorylation 
of eukaryotic translation initiation factor 2 alpha. J Bone Miner Metab. 2013; 31:618–628. 
[PubMed: 23536193] 
127. Hamamura K, Yokota H. Stress to endoplasmic reticulum of mouse osteoblasts induces apoptosis 
and transcriptional activation for bone remodeling. FEBS Lett. 2007; 581:1769–1774. [PubMed: 
17418825] 
128. Saito A, Ochiai K, Kondo S, et al. Endoplasmic reticulum stress response mediated by the PERK-
eIF2(alpha)-ATF4 pathway is involved in osteoblast differentiation induced by BMP2. J Biol 
Chem. 2011; 286:4809–4818. [PubMed: 21135100] 
129. Sato AY, Cregor M, Delgado-Calle J, et al. Protection from glucocorticoid-induced osteoporosis 
by anti-catabolic signaling in the absence of Sost/sclerostin. J Bone Miner Res. 2016; 31:1791–
1802. [PubMed: 27163932] 
130. Piemontese M, Xiong J, Fujiwara Y, et al. Cortical bone loss caused by glucocorticoid excess 
requires RANKL production by osteocytes and is associated with reduced OPG expression in 
mice. Am J Physiol Endocrinol Metab. 2016; 311:E587–E593. [PubMed: 27460899] 
131. Weinstein RS, Roberson PK, Manolagas SC. Giant osteoclast formation and long-term oral 
bisphosphonate therapy. N Engl J Med. 2009; 360:53–62. [PubMed: 19118304] 
132. Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to 
treatments. Nat Med. 2013; 19:179–192. [PubMed: 23389618] 
133. Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the 
deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001; 10:537–543. [PubMed: 
11181578] 
134. Dixon JM, Cull RE, Gamble P. Two cases of Van Buchem’s disease. J Neurol Neurosurg 
Psychiatry. 1982; 45:913–918. [PubMed: 6754874] 
135. Leupin O, Piters E, Halleux C, et al. Bone overgrowth-associated mutations in the LRP4 gene 
impair sclerostin facilitator function. J Biol Chem. 2011; 286:19489–19500. [PubMed: 
21471202] 
Sato et al. Page 20
Clin Rev Bone Miner Metab. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
136. Glass DA, Bialek P, Ahn JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls 
osteoclast differentiation. Dev Cell. 2005; 8:751–764. [PubMed: 15866165] 
137. Holmen SL, Zylstra CR, Mukherjee A, et al. Essential role of beta-catenin in postnatal bone 
acquisition. J Biol Chem. 2005; 280:21162–21168. [PubMed: 15802266] 
138. Jilka, RL., Bellido, T., Almeida, M., Plotkin, LI., O’Brien, CA., Weinstein, RS., Manolagas, SC. 
Apoptosis in bone cells. In: Bilezikian, JP.Raisz, LG., Martin, TJ., editors. Principles of Bone 
Biology. Academic Press; San Diego, San Francisco, New York, London, Sydney, Tokyo: 2008. 
p. 237-261.
139. Marenzana M, Greenslade K, Eddleston A, et al. Sclerostin antibody treatment enhances bone 
strength but does not prevent growth retardation in young mice treated with dexamethasone. 
Arthritis Rheum. 2011; 63:2385–2395. [PubMed: 21484764] 
140. Yao W, Dai W, Jiang L, et al. Sclerostin-antibody treatment of glucocorticoid-induced 
osteoporosis maintained bone mass and strength. Osteoporos Int. 2016; 27:283–294. [PubMed: 
26384674] 
141. van Lierop AH, Hamdy NA, Papapoulos SE. Glucocorticoids are not always deleterious for bone. 
J Bone Miner Res. 2010; 25:2796–2800. [PubMed: 20549703] 
142. Rizzoli R, Adachi JD, Cooper C, et al. Management of glucocorticoid-induced osteoporosis. 
Calcif Tissue Int. 2012; 91:225–243. [PubMed: 22878667] 
143. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of 
glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study 
Group. N Engl J Med. 1998; 339:292–299. [PubMed: 9682041] 
144. Mok CC, Ho LY, Ma KM. Switching of oral bisphosphonates to denosumab in chronic 
glucocorticoid users: a 12-month randomized controlled trial. Bone. 2015; 75:222–228. 
[PubMed: 25761434] 
145. Allen MR, Iwata K, Phipps R, et al. Alterations in canine vertebral bone turnover, microdamage 
accumulation, and biomechanical properties following 1-year treatment with clinical treatment 
doses of risedronate or alendronate. Bone. 2006; 39:872–879. [PubMed: 16765660] 
146. Mashiba T, Turner CH, Hirano T, et al. Effects of suppressed bone turnover by bisphosphonates 
on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites 
in beagles. Bone. 2001; 28:524–531. [PubMed: 11344052] 
147. O’Ryan FS, Khoury S, Liao W, et al. Intravenous bisphosphonate-related osteonecrosis of the 
jaw: bone scintigraphy as an early indicator. J Oral Maxillofac Surg. 2009; 67:1363–1372. 
[PubMed: 19531404] 
148. Allen MR, Burr DB. Mineralization, Microdamage, and Matrix: How Bisphosphonates Influence 
Material Properties of Bone. BoneKEy-osteovision. 2007; 4:49–60.
149. Minetto MA, Botter A, Lanfranco F, et al. Muscle fiber conduction slowing and decreased levels 
of circulating muscle proteins after short-term dexamethasone administration in healthy subjects. 
J Clin Endocrinol Metab. 2010; 95:1663–1671. [PubMed: 20139231] 
150. Minetto MA, Qaisar R, Agoni V, et al. Quantitative and qualitative adaptations of muscle fibers to 
glucocorticoids. Muscle Nerve. 2015; 52:631–639. [PubMed: 25594832] 
151. Schakman O, Kalista S, Barbe C, et al. Glucocorticoid-induced skeletal muscle atrophy. Int J 
Biochem Cell Biol. 2013; 45:2163–2172. [PubMed: 23806868] 
152. Sandri M, Lin J, Handschin C, et al. PGC-1alpha protects skeletal muscle from atrophy by 
suppressing FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci U S A. 
2006; 103:16260–16265. [PubMed: 17053067] 
153. Bodine SC, Latres E, Baumhueter S, et al. Identification of ubiquitin ligases required for skeletal 
muscle atrophy. Science. 2001; 294:1704–1708. [PubMed: 11679633] 
154. Gomes MD, Lecker SH, Jagoe RT, et al. Atrogin-1, a muscle-specific F-box protein highly 
expressed during muscle atrophy. Proc Natl Acad Sci U S A. 2001; 98:14440–14445. [PubMed: 
11717410] 
155. Menconi M, Gonnella P, Petkova V, et al. Dexamethasone and corticosterone induce similar, but 
not identical, muscle wasting responses in cultured L6 and C2C12 myotubes. J Cell Biochem. 
2008; 105:353–364. [PubMed: 18615595] 
Sato et al. Page 21
Clin Rev Bone Miner Metab. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
156. Furlow JD, Watson ML, Waddell DS, et al. Altered gene expression patterns in muscle ring finger 
1 null mice during denervation- and dexamethasone-induced muscle atrophy. Physiol Genomics. 
2013; 45:1168–1185. [PubMed: 24130153] 
157. Baehr LM, Furlow JD, Bodine SC. Muscle sparing in muscle RING finger 1 null mice: response 
to synthetic glucocorticoids. J Physiol. 2011; 589:4759–4776. [PubMed: 21807613] 
158. Watson ML, Baehr LM, Reichardt HM, et al. A cell-autonomous role for the glucocorticoid 
receptor in skeletal muscle atrophy induced by systemic glucocorticoid exposure. Am J Physiol 
Endocrinol Metab. 2012; 302:E1210–E1220. [PubMed: 22354783] 
159. Sartori R, Schirwis E, Blaauw B, et al. BMP signaling controls muscle mass. Nat Genet. 2013; 
45:1309–1318. [PubMed: 24076600] 
160. Kondo H, Ezura Y, Nakamoto T, et al. MURF1 deficiency suppresses unloading-induced effects 
on osteoblasts and osteoclasts to lead to bone loss. J Cell Biochem. 2011; 112:3525–3530. 
[PubMed: 21866567] 
161. Fournier M, Huang ZS, Li H, et al. Insulin-like growth factor I prevents corticosteroid-induced 
diaphragm muscle atrophy in emphysematous hamsters. Am J Physiol Regul Integr Comp 
Physiol. 2003; 285:R34–R43. [PubMed: 12689851] 
162. Dekhuijzen PN, Gayan-Ramirez G, Bisschop A, et al. Corticosteroid treatment and nutritional 
deprivation cause a different pattern of atrophy in rat diaphragm. J Appl Physiol. 1995; 78:629–
637. [PubMed: 7759433] 
163. Rosenblatt JD, Parry DJ. Gamma irradiation prevents compensatory hypertrophy of overloaded 
mouse extensor digitorum longus muscle. J Appl Physiol (1985). 1992; 73:2538–2543. [PubMed: 
1490967] 
164. Falduto MT, Czerwinski SM, Hickson RC. Glucocorticoid-induced muscle atrophy prevention by 
exercise in fast-twitch fibers. J Appl Physiol. 1990; 69:1058–1062. [PubMed: 2246153] 
165. Sandri M, Sandri C, Gilbert A, et al. Foxo transcription factors induce the atrophy-related 
ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 2004; 117:399–412. [PubMed: 
15109499] 
166. Milan G, Romanello V, Pescatore F, et al. Regulation of autophagy and the ubiquitin-proteasome 
system by the FoxO transcriptional network during muscle atrophy. Nat Commun. 2015; 6:6670. 
[PubMed: 25858807] 
167. Mourikis P, Sambasivan R, Castel D, et al. A critical requirement for notch signaling in 
maintenance of the quiescent skeletal muscle stem cell state. Stem Cells. 2012; 30:243–252. 
[PubMed: 22069237] 
168. Wen Y, Bi P, Liu W, et al. Constitutive Notch activation upregulates Pax7 and promotes the self-
renewal of skeletal muscle satellite cells. Mol Cell Biol. 2012; 32:2300–2311. [PubMed: 
22493066] 
169. Buas MF, Kabak S, Kadesch T. The Notch effector Hey1 associates with myogenic target genes to 
repress myogenesis. J Biol Chem. 2010; 285:1249–1258. [PubMed: 19917614] 
170. Kopan R, Nye JS, Weintraub H. The intracellular domain of mouse Notch: a constitutively 
activated repressor of myogenesis directed at the basic helix-loop-helix region of MyoD. 
Development. 1994; 120:2385–2396. [PubMed: 7956819] 
171. Pereira RM, Delany AM, Durant D, et al. Cortisol regulates the expression of Notch in 
osteoblasts. J Cell Biochem. 2002; 85:252–258. [PubMed: 11948681] 
172. Xu J, Li R, Workeneh B, et al. Transcription factor FoxO1, the dominant mediator of muscle 
wasting in chronic kidney disease, is inhibited by microRNA-486. Kidney Int. 2012; 82:401–411. 
[PubMed: 22475820] 
173. Ambrogini E, Almeida M, Martin-Millan M, et al. FoxO-Mediated Defense against Oxidative 
Stress in Osteoblasts Is Indispensable for Skeletal Homeostasis in Mice. Cell Metab. 2010; 
11:136–146. [PubMed: 20142101] 
Sato et al. Page 22
Clin Rev Bone Miner Metab. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. Adverse effects of GC in the musculoskeletal system
A. Percent occurrence of adverse effects in bone and muscle with endogenous or exogenous 
GC excess. B. Comparison of fracture and osteonecrosis occurrence in specific bones 
induced by endogenous and exogenous GC excess. C. GC metabolism: Inactive GC 
metabolites are converted to active metabolites and vice versa by the enzymatic activity of 
11β-HSD 1 and 2, respectively. Active GC metabolites bind to the glucocorticoid receptor to 
initiate the GC response. D. Relative potency of active GC analogs. References in the graph 
and tables correspond to data sources. See abbreviations in text.
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Figure 2. Mechanisms of action of GC on bone cells
GC induce an early increase in osteoclasts and a decrease in osteoblasts and osteoid 
production. The early increase in osteoclasts is due to prolongation of survival of preexisting 
osteoclasts and stimulation of osteoclastogenesis via increased RANKL/OPG ratio, through 
combined downregulation of OPG and upregulation of RANKL expression in osteoblasts 
and osteocytes. GC also induce apoptosis of osteoblasts and osteocytes through activation of 
the Pyk2 kinase, and accumulation of ROS and the resulting endoplasmic reticulum (ER) 
stress. GC inhibit the synthetic capacity of osteoblasts through suppression of OCN and Col 
1a1 transcription. Osteocytic Sost/sclerostin expression is increased by GC, which reduces 
Wnt/β-catenin signaling in the bone microenvironment, with the consequent decreased in 
OPG expression in osteocytes and osteoblasts. Table summarizes GC effects at the tissue and 
cellular levels. The early phase of GC-induced bone disease is due to increased osteoclasts 
and bone resorption and decreased osteoblasts and bone formation. The late, chronic disease 
phase is associated with decreased osteoclasts and osteoblasts, leading to a low bone 
remodeling state. Increased osteocyte apoptosis in both phases of GC-induced bone disease 
contributes to decreased bone strength by disrupting the function of the osteocytic lacunar-
canalicular network.
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Figure 3. Regulation of atrophy-related genes in muscle and bone by GC
GC activate distinct pathways in muscle and bone that converge in the upregulation of 
atrophy-related E3 ubiquitin ligase genes or atrogens (atrogin1, MuRF1, and MUSA1); these 
in turn lead to atrophy and loss of mass in both tissues (sarcopenia and osteopenia). The 
combined adverse effects of GC in bone and muscle contribute to GC-induced myopathy 
and the increased occurrence of bone fractures.
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